Publication | Closed Access

Effects of SGLT2 selective inhibitor ipragliflozin on hyperglycemia, hyperlipidemia, hepatic steatosis, oxidative stress, inflammation, and obesity in type 2 diabetic mice

ObesityMetabolic SyndromeInflammationDiabetes ManagementMedicinePhysiologyDiabetesType 2Diabetic MiceDiabetes MellitusPharmacologyOxidative StressHealth Sciences